GlassScriptPhysician profile
Luis E Villaplana
NPI 1992766638
$3,846.65
in general payments reported to CMS, 2019-2025
34 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.81 · 2020: $69.32 · 2021: $379 · 2022: $770 · 2023: $707 · 2024: $725 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,563.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $994.31 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $345.00 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $234.32 | 2019-2024 | Vivitrol, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.63 | 2020-2025 | Caplyta |
| Indivior INC. | $191.17 | 2019-2024 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $178.29 | 2025 | Airsupra, Farxiga, Breztri |
| Evoke Pharma, INC. | $167.59 | 2022-2023 | Gimoti |
| Lundbeck LLC | $156.35 | 2022-2025 | Abilify Maintena, Rexulti |
| Lilly USA, LLC | $116.90 | 2022-2025 | Mounjaro |
| Novo Nordisk INC | $113.72 | 2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $92.17 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $85.84 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $81.97 | 2025 | Gvoke Hypopen, Recorlev |
| Recordati_rare_diseases_inc. | $78.01 | 2025 | Isturisa |
| Janssen Pharmaceuticals, INC | $72.09 | 2023 | Invega Sustenna, Invega Trinza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $68.39 | 2024-2025 | Xyosted |
| Amgen INC. | $64.80 | 2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.86 | 2022-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $60.54 | 2021-2024 | Ingrezza |
| Orexo US, INC. | $56.38 | 2019-2024 | Zubsolv |
| Abbott Laboratories | $53.12 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.92 | 2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $41.20 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $35.28 | 2023-2025 | Auvelity |
| Sumitomo Pharma America, INC. | $33.05 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $29.59 | 2024-2025 | Austedo Xr, Austedo Xr |
| Braeburn INC. | $29.54 | 2023 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $29.34 | 2022-2024 | Cobenfy |
| Noven Therapeutics, LLC | $28.11 | 2021 | |
| Vanda Pharmaceuticals INC. | $23.09 | 2024 | Fanapt |
| Azurity Pharmaceuticals, INC. | $20.69 | 2025 | Edarbi |
| Validus Pharmaceuticals LLC | $18.07 | 2023 | Equetro |
| Halozyme INC | $16.53 | 2023 | |
| Supernus Pharmaceuticals, INC. | $14.79 | 2024 | Xyosted, Tlando, Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Villaplana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.